This CPB is revised to state that bortezomib for subcutaneous or intravenous administration is considered medically necessary when criteria are met.  This CPB is revised to state that bortezomib is considered experimental and investigational for the following indications: splenic marginal zone lymphoma, gastric MALT lymphoma, non-gastric MALT lymphoma, and follicular lymphoma.